首页> 外文OA文献 >Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score results

【2h】

Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score results

机译：基于21-基因测定复发评分结果的激素受体阳性早期乳腺癌城乡妇女的治疗差异

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Molly Andreason; Chong Zhang; Adedayo Onitilo; Jessica Engel; Wendy Ledesma; Kimberly Ridolfi; KyungMann Kim; John Charlson; Kari Wisinski; Amye Tevaarwerk;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2enegative early-stage breast cancer [J] . Albanell Joan, Svedman Christer, Gligorov Joseph, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：欧洲前瞻性研究的汇总分析，评估了使用21基因复发评分法对雌激素受体阳性，人表皮生长因子受体2阴性的早期乳腺癌女性临床决策的影响
2. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2enegative early-stage breast cancer [J] . Albanell Joan, Svedman Christer, Gligorov Joseph, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：汇总分析预期欧洲研究评估使用21-基因复发得分测定对雌激素受体阳性，人表皮生长因子受体2Enegative早期乳腺癌患者临床决策的影响
3. The 21-gene Recurrence Score? assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial) [J] . Frédérique Penault-Llorca, Thomas Filleron, Bernard Asselain, BMC Cancer . 2018,第1期

机译：21基因复发评分？检测可预测以辅助依序表柔比星和多西紫杉醇或表柔比星化疗的淋巴结阳性，激素受体阳性，乳腺癌患者的远处复发（PACS-01试验）
4. Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive Assays [C] . Frederick L. Baehner International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：雌激素受体阳性乳腺癌：传统预测，分子病理：新的乳腺癌分类和21世纪个性化预测和预测测定
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score results [O] . Molly Andreason, Chong Zhang, Adedayo A Onitilo, -1

机译：基于21基因分析复发评分结果的激素受体阳性早期乳腺癌城市和农村妇女的治疗差异
7. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. [O] . Albanell Mestres, Joan, Svedman, Christer, Gligorov, Joseph, 2016

机译：汇总分析前瞻性欧洲研究，评估使用21基因复发评分测定对雌激素受体阳性，人表皮生长因子受体2阴性早期乳腺癌患者临床决策的影响。

Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score results

著录项

引文网络

相似文献

相关主题

期刊订阅